50 Hampshire Street
4 articles with EQRX
Primary Endpoint Met in Phase 3 Study of the Anti-PD-L1 Antibody Sugemalimab in Stage III Non-Small Cell Lung Cancer
Sugemalimab is the first PD(L)1 monoclonal antibody to demonstrate a progression-free survival benefit in Stage III non-small cell lung cancer (NSCLC) patients after treatment with either concurrent or sequential chemoradiotherapy
EQRx , a company committed to developing and delivering important new medicines at lower prices, today announced two key leadership appointments to advance the company’s mission of remaking medicine. Jami Rubin joins as chief financial officer to guide the strategic financial direction of the Company, effective April 5.
EQRx Scales Disruptive Model of Important New Medicines at Lower Prices with $500M Series B Financing
Syndicate includes all Series A investors, preeminent life science and generalist funds, and market-leading health systems and payers
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.